光大证券股份有限公司 关于浙江东方基因生物制品股份有限公司 2024 年度募集资金存放与实际使用情况的专项核查意见 光大证券股份有限公司(以下简称"光大证券"或"保荐机构")作为浙江 东方基因生物制品股份有限公司(以下简称"东方生物"或"公司") 首次公 开发行股票并在科创板上市项目的保荐机构,根据《证券发行上市保荐业务管理 办法》《上市公司监管指引第2号 -- 上市公司募集资金管理和使用的监管要求 (2022年修订)》《上海证券交易所科创板股票上市规则》《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》等相关规定履行持续督导职 责,对东方生物 2024年度募集资金的存放与实际使用情况进行核查,核查情况 如下: 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可[2019]2999 号文《关于同意浙江东方基 因生物制品股份有限公司首次公开发行股票注册的批复》同意,公司于 2020 年 1 月 22 日向社会公众首次公开发行人民币普通股(A 股)3,000 万股,每股发行价 格为 21.25 元, 募集资金总额 637,500,000.00 元,扣除 ...

浙江东方基因生物制品股份有限公司 审计报告及财务报表 二〇二四年度 此 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进 打牛 2 浙江东方基因生物制品股份有限公司 审计报告及财务报表 (2024年01月01日至2024年12月31日止) | 目录 | 页次 | | --- | --- | | 审计报告 | 1-4 | | 财务报表 | | | 合并资产负债表和母公司资产负债表 | 1-4 | | 合并利润表和母公司利润表 | 5-6 | | 合并现金流量表和母公司现金流量表 | 7-8 | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | 财务报表附注 | 1-104 | 立信会计师事务所(特殊普通合伙 DO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LL 审计报告 信会师报字[2025]第 ZF10664 号 浙江东方基因生物制品股份有限公司全体股东: 一、审计意见 我们审计了浙江东方基因生物制品股份有限公司(以下简称东方 生物公司)财务报表,包括 2024年12月 31 目 ...

浙江东方基因生物制品股份有限公司 独立董事对公司 2024年度对外担保情况的专项说明 根据《上市公司监管指引第 8号 -- 上市公司资金往来、对外担保的监管要 求》《上海证券交易所科创板股票上市规则》相关规定和要求,我们作为浙江东 方基因生物制品股份有限公司(简称"公司")的独立董事,我们本着认真负责、 实事求是的态度,对公司 2024年度对外担保事项进行了审慎的监督和核查,现 发表如下专项说明: 一、关于公司对外担保情况的专项说明及意见 (1)经仔细审阅公司 2024年度经审计的财务报告,报告期内公司及其合并 报表范围内子公司不存在为控股股东、实际控制人及其关联方提供担保的情况。 (2)经核查,报告期内,公司于2024年2月7日,公司召开第三届董事会 第六次会议审议通过《关于为全资子公司英国爱可生物科技有限公司提供担保的 议案》,拟为全资子公司英国爱可向苏格兰商业局申请研发商业补贴提供连带责 任担保 975,556.00 英镑担保,本次担保事项无需提交股东大会审议。截至报告 期末,该担保事项尚未实际执行; 公司于 2024年 12月 27 日召开第三届董事会第十一次会议、第三届监事会 第十次会议审议通过《关 ...

浙江东方基因生物制品股份有限公司 2024年度独立董事述职报告(李波) 各位董事: (二)是否存在影响独立性的情况说明 作为公司独立董事,我本人及直系亲属、主要社会关系均不在公司或其子公 司任职,且未在公司关联企业任职;没有为公司或其附属公司提供财务、法律、 咨询等服务;本人未在公司担任除独立董事以外的任何职务。同时按照《上市公 司独立董事管理办法》《上海证券交易所科创板股票上市规则》等相关规定,本 人具备法律法规所要求的独立性,并在履职中保持客观、独立的专业判断,不存 在影响独立性的情况。 二、独立董事年度履职概况 (一) 出席会议情况 1、出席董事会会议、股东大会情况 本人作为浙江东方基因生物制品股份有限公司(以下简称"东方生物"或"公 司"、"本公司")独立董事,严格按照《公司法》《上市公司独立董事管理办法》 《上海证券交易所科创板股票上市规则》等相关法律法规和《公司章程》《独立 董事工作制度》等相关规定和要求,认真履行独立董事职责,充分行使独立董事 职权,勤勉尽责,切实维护了公司整体利益和全体股东的合法权益。现将本人 2024年度履职情况汇报如下: 报告期内,公司累计召开董事会 6 次,股东大会 3 ...

浙江东方基因生物制品股份有限公司 2024年度独立董事述职报告(王晓燕) 各位董事: 我本人作为浙江东方基因生物制品股份有限公司(以下简称"东方生物"或 "公司"、"本公司")独立董事,严格按照《公司法》《上市公司独立董事管理办 法》《上海证券交易所科创板股票上市规则》等相关法律法规和《公司章程》《独 立董事工作制度》等相关规定和要求,认真履行独立董事职责,充分行使独立董 事职权,勤勉尽责,切实维护了公司整体利益和全体股东的合法权益。现将本人 2024年度履职情况汇报如下: 一、公司独立董事的基本情况 报告期内,公司累计召开董事会 6 次,股东大会 3 次,本人自任职以来,积 极参加公司的董事会和股东大会,认真审阅相关材料,积极参与各议案的讨论并 提出合理的建议,本着审慎客观的原则,以勤勉负责的态度,充分发挥专业作用, 切实维护公司和全体股东的利益。 2024年度,本人共参加了 6 次董事会、3 次股东大会,认真审议各项议案, 均能充分发表自己的意见和建议,相关审议议案均投了同意票,公司董事会 2024 年度审议的所有议案全部表决通过,本年度出席会议情况如下: | 独立重 | | | 出席董事会情况 | | ...

浙江东方基因生物制品股份有限公司 2024 年度独立董事述职报告(张红英) 各位董事: 我本人作为浙江东方基因生物制品股份有限公司(以下简称"东方生物"或 "公司"、"本公司")独立董事,严格按照《公司法》《上市公司独立董事管理办 法》《上海证券交易所科创板股票上市规则》等相关法律法规和《公司章程》《独 立董事工作制度》等相关规定和要求,认真履行独立董事职责,充分行使独立董 事职权,勤勉尽责,切实维护了公司整体利益和全体股东的合法权益。 现将本人 2024年度履职情况汇报如下: 一、公司独立董事的基本情况 张红英女士,1966年5月出生,中国国籍,无境外永久居留权,1988年7 月至今在浙江财经大学会计学院工作:历任会计学院社会合作办、校友办主任, 国际注册内部审计师、副教授,硕士生导师;2005年至2013年任会计学院党总 支副书记;2013年至2020 任会计学院党委书记;2020年至今担任会计学院社会 合作办、校友办主任,2021年4月至今兼任浙江财经大学教育基金会理事长。 2017年4月至2023年4月任浙江君亭酒店股份有限公司独立董事;2019年2 月至今任南华期货股份有限公司独立董事;2019年1 ...

暨现金分红说明会的公告 证券代码：688298 证券简称：东方生物 公告编号：2025-021 浙江东方基因生物制品股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 05 月 15 日（星期四）09:00-10:00 投资者可于 2025 年 05 月 08 日（星期四）至 05 月 14 日（星期三）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqb@orien tgene.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 浙江东方基因生物制品股份有限公司（以下简称"公司"）已于 2025 年 4 月 30 日发布公司 2024 年度报告及 2025 年第一季度报告，为便于广大投资者更 全面深入地了解公司 2024 年度及 2025 年第一季度经营成果、财务状况，公司计 划于 2025 年 05 月 15 日 （星期四） 09:00-10:00 举行 2024 年度 ...

Market Expansion and Acquisitions - In 2024, the company accelerated the construction of production and research bases in multiple locations, including the US, enhancing its local market presence through acquisitions such as Confirm and Hualong Agricultural[3]. - The company established a large-scale POCT production base in the US, with dozens of automated production lines to support local orders[3]. - The acquisition of Confirm in the US facilitated the establishment of local retail channels, while the acquisition of Laihe in Hangzhou complemented the company's product offerings in infectious disease testing[49]. - New subsidiaries were established in Germany and the Philippines to enhance market presence in Europe and Southeast Asia[50]. - The company is considering strategic acquisitions to enhance its product portfolio and expand its capabilities[26]. - The company has completed the acquisition of an animal vaccine business module, diversifying its operations into the animal health sector alongside human diagnostics[55]. - The company has initiated three acquisition projects, resulting in increased sales and management expenses[155]. Financial Performance - The company's net profit attributable to shareholders for the year 2024 is reported as -RMB 529,022,760.88, indicating a negative performance[17]. - The net profit attributable to shareholders for 2024 was approximately -¥529.02 million, a decrease of 33.06% from -¥397.58 million in 2023[36]. - The company has repurchased a total of 8.4036 million shares in 2024, with a total repurchase amount of RMB 277 million, which is 52.35% of the absolute value of the net profit attributable to shareholders[18]. - No cash dividends or capital reserve transfers to increase share capital will be distributed for the year 2024 due to the negative net profit[17]. - The company's operating revenue for 2024 was approximately ¥827.92 million, representing a 0.95% increase compared to ¥820.16 million in 2023[36]. - The net cash flow from operating activities improved significantly to -¥348.33 million in 2024, a 78.83% increase compared to -¥1.65 billion in 2023[36]. - The gross profit margin has decreased by 12.04% year-on-year, primarily due to changes in product sales structure and market factors[157]. Research and Development - Research and development expenses accounted for 35.09% of operating revenue in 2024, an increase of 3.28 percentage points from 31.81% in 2023[37]. - The company is investing in research and development, particularly in immunodiagnostic and molecular diagnostic technologies, to innovate and improve product offerings[58]. - The company has developed a comprehensive core technology portfolio, including platforms for POCT, molecular diagnostics, and flow fluorescence, with over 1,000 products in its pipeline[109]. - The company has achieved breakthroughs in zoonotic disease detection products, contributing to the safety and health of livestock farming in China[117]. - The company has made significant investments in R&D, focusing on rapid nucleic acid detection technologies and portable PCR devices, improving efficiency in molecular diagnostics[113]. Product Development and Innovation - The company reported a significant increase in revenue, achieving a total of $150 million, representing a 25% year-over-year growth[26]. - New product launches are expected to contribute an additional $20 million in revenue over the next six months[26]. - The company is focusing on expanding its product line in oncology diagnostics, with tests for various tumor markers such as AFP and PSA[59]. - The company has launched new technologies for infectious disease testing, including nucleic acid detection for multiple viruses[59]. - The introduction of molecular diagnostic products has expanded to include quantitative detection for HBV, HCV, and HIV-1, enhancing the company's testing portfolio[59]. Market Trends and Industry Insights - The global in vitro diagnostic (IVD) market is projected to reach approximately $109.2 billion by 2024, with an annual growth rate of 4.3% expected to reach $135.1 billion by 2029[72]. - The domestic IVD market is experiencing rapid growth, driven by policies supporting domestic enterprises and the acceleration of domestic substitution, with significant potential for future expansion[72]. - The trend towards home testing (POCT) is expanding, particularly in the context of infectious and chronic diseases, as consumer confidence in home testing increases[65]. - The integration of AI and automation in IVD devices is becoming a focal point for leading companies, enhancing diagnostic efficiency and accuracy[67]. - The industry is witnessing increased market concentration, with leading companies rapidly expanding through mergers and acquisitions, while smaller firms face heightened survival pressures[68]. Operational Efficiency and Cost Management - The company aims to reduce unit product costs and optimize expense ratios in 2025, targeting improvements in production efficiency and cost management[9]. - Cost management strategies have resulted in a 10% reduction in operational expenses, improving overall profitability[26]. - A focus on enhancing operational efficiency is expected to reduce costs by approximately 10% over the next fiscal year[58]. - The company is actively addressing potential tariff impacts from US trade policies by optimizing its market layout and reducing product costs[11]. Compliance and Legal Matters - The company is engaged in legal proceedings related to a lawsuit filed against it in the US, with professional legal teams managing the situation[12]. - The company has received a standard unqualified audit report from the accounting firm[16]. - There are no violations of decision-making procedures regarding external guarantees[21]. Strategic Partnerships and Collaborations - A new partnership with a leading healthcare provider is expected to enhance service delivery and increase customer satisfaction[26]. - The company has established strategic partnerships with major clients such as McKesson, Walmart, and Siemens Healthineers, enhancing its market reach[127].

Financial Performance - The company's operating revenue for Q1 2025 was ¥191,951,815.38, representing a 4.94% increase compared to ¥182,922,481.69 in the same period last year[4] - The net profit attributable to shareholders was -¥115,452,483.95, a decrease of 71.41% from -¥67,353,495.40 year-over-year[4] - The basic and diluted earnings per share were both -¥0.57, a decline of 72.73% compared to -¥0.33 in the same period last year[4] - The weighted average return on equity was -1.75%, down from -0.91% year-over-year[4] - Net loss for Q1 2025 was CNY 120,770,122.94, compared to a net loss of CNY 69,955,283.74 in Q1 2024, representing an increase in loss of 72.6%[20] - Operating profit for Q1 2025 was CNY -123,486,375.38, worsening from CNY -67,454,742.43 in Q1 2024[19] - The company reported a total comprehensive loss of CNY -128,591,327.44 for Q1 2025, compared to CNY -78,308,185.85 in Q1 2024[20] Cash Flow - The net cash flow from operating activities improved by 74.38%, reaching -¥54,288,610.17, compared to -¥211,864,976.91 in the previous year[4] - Operating cash inflow totaled $276,022,567.96, an increase from $228,718,943.11 in the previous period, reflecting a growth of approximately 20.8%[24] - Cash inflow from investment activities reached $1,466,438,459.32, significantly higher than $539,083,927.86 in the prior period, marking an increase of about 172.6%[25] - Cash inflow from financing activities amounted to $239,000,000.00, up from $105,960,000.00, representing an increase of approximately 125%[25] - The ending cash and cash equivalents balance was $1,038,630,348.81, down from $2,595,292,577.44 year-over-year[25] Assets and Liabilities - Total assets decreased by 4.14% to ¥7,759,161,951.63 from ¥8,094,580,246.54 at the end of the previous year[5] - The company reported a total current assets of RMB 3,583,909,471.49 as of March 31, 2025, down from RMB 3,978,764,707.92 at the end of 2024, representing a decrease of approximately 9.9%[14] - Total liabilities decreased to CNY 1,094,430,122.43 in Q1 2025 from CNY 1,303,147,089.90 in Q1 2024, a decline of 15.9%[16] - The company's total equity decreased to CNY 6,664,731,829.20 in Q1 2025 from CNY 6,791,433,156.64 in Q1 2024, a decrease of 1.9%[16] Research and Development - Research and development expenses totaled ¥58,725,780.47, accounting for 30.59% of operating revenue, down from 39.34% in the previous year[5] - Research and development expenses for Q1 2025 were CNY 58,725,780.47, down 18.3% from CNY 71,964,517.95 in Q1 2024[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,778[9] - The top three shareholders collectively hold 48.56% of the company's shares, with Anji Fulanglai holding 19.5%, Fangs Holdings Limited at 18.75%, and Anji Yongwei at 10.31%[11] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[12] Legal Matters - The company is currently facing a lawsuit from FS Medical Supplies, LLC, claiming damages not less than USD 1 billion, along with additional compensatory damages of at least USD 250 million[12] - The company has engaged legal counsel to respond to the lawsuit and is also pursuing legal action against FS Medical Supplies, LLC in China[13] - As of the report date, the lawsuit has not impacted the company's financial results for the reporting period[13] Inventory and Receivables - Cash and cash equivalents decreased to RMB 2,604,809,193.17 from RMB 3,081,496,804.80, reflecting a decline of about 15.4%[14] - Accounts receivable decreased to RMB 191,096,239.50 from RMB 228,082,280.19, a reduction of about 16.2%[14] - Inventory decreased slightly to RMB 296,948,644.63 from RMB 308,960,712.66, indicating a decrease of around 3.9%[14]

东方生物公告，2025年第一季度营收为1.92亿元，同比增长4.94%；净亏损1.15亿元，去年同期净亏损 6735.35万元。 ...